Cargando…

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)

Detalles Bibliográficos
Autores principales:	Phillips, Adrienne, Fields, Paul, Hermine, Olivier, Taylor, Graham P, Delioukina, Maria, Horwitz, Steven, Ramos, Juan C, Meniane, Jean-Côme, Barta, Stefan K, Brites, Carlos, Pereria, Juliana, Beltran, Brady, Casanova, Luis, Wandroo, Farooq, Feldman, Tatyana, Dwyer, Karen, Kurman, Michael, Conlon, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578121/ http://dx.doi.org/10.1186/1742-4690-12-S1-P31

Ejemplares similares

Promising results of an anti-CCR4 antibody, KW-0761, for relapsed Adult T-Cell Leukemia-Lymphoma (ATL)
por: Utsunomiya, Atae, et al.
Publicado: (2011)

Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors
por: Saito, Takuro, et al.
Publicado: (2021)

Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
por: Phillips, Adrienne A., et al.
Publicado: (2019)

Humanized anti CCR4 antibody KW0761 targets HTLV-1 infected CD4+ CCR4+ and CD8+CCR4+ T cells to treat HAM/TSP
por: Yamano, Yoshihisa, et al.
Publicado: (2015)

Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors
por: Fujikawa, Kaoru, et al.
Publicado: (2023)

Effects of valproate on Tax and HBZ expression in ex vivo cultured ATL cells
por: Belrose, Gildas, et al.
Publicado: (2014)

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management
por: Musiek, Amy C. M., et al.
Publicado: (2021)

Immunohistochemistry for CCR4 C‐terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T‐cell leukemia/lymphoma
por: Fujii, Keiichiro, et al.
Publicado: (2020)

Can we cure ATL: new drugs and targeting ATL stem cells
por: Hermine, Olivier
Publicado: (2014)

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas
por: Kitadate, Akihiro, et al.
Publicado: (2018)

CCR7 alterations associated with inferior outcome of adult T‐cell leukemia/lymphoma under mogamulizumab treatment
por: Sakamoto, Yuma, et al.
Publicado: (2022)

Mogamulizumab, an anti-CCR4 monoclonal antibody, is a potent therapeutic option for adult T-cell leukemia-lymphoma
por: Utsunomiya, Atae
Publicado: (2014)

ATL internals: working with ATL 8
por: Tavares, Chris
Publicado: (2006)

Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
por: Horwitz, Steven, et al.
Publicado: (2021)

Cutaneous adverse reactions and anti-tumor effects of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma
por: Yonekura, Kentro, et al.
Publicado: (2015)

Alopecia areata after mogamulizumab treatment
por: Raval, Neel S., et al.
Publicado: (2021)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Tax as a therapeutic target in ATL
por: Dassouki, Zeina, et al.
Publicado: (2015)

Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma
por: Bagot, Martine, et al.
Publicado: (2022)

ATL internals
por: Rector, Brent, et al.
Publicado: (1999)

ATL internals /
por: Rector, Brent
Publicado: (1999)

Dr. Atl /
por: Luna Arroyo, Antonio
Publicado: (1992)

Alopecia areata-like presentations with mogamulizumab therapy
por: Kincaid, Colin M., et al.
Publicado: (2023)

Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: retrospective study in Martinique
por: Baubion, Emilie, et al.
Publicado: (2015)

Marketing approval of mogamulizumab: A triumph for glyco-engineering
por: Beck, Alain, et al.
Publicado: (2012)

Recurrent TET2 mutations in adult T cell leukemia (ATL) and identification of a Single Nucleotide polymorphism in TET2 region predisposing to ATL development
por: Marçais, Ambroise, et al.
Publicado: (2015)

Dr. Atl : pinturas y dibujos /
por: Atl, Dr., 1875-1964
Publicado: (1974)

Dr. Atl : el paisaje como pasión /
por: Espejo, Beatriz
Publicado: (1994)

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
por: Ollila, Thomas A, et al.
Publicado: (2019)

Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma
por: Kwan, Jennifer M., et al.
Publicado: (2021)

Dr. Atl : paisaje de hielo y fuego /
por: Roura, Alma Lilia
Publicado: (1999)

Clinical Trials and Treatment of ATL
por: Tsukasaki, Kunihiro, et al.
Publicado: (2012)

Contralateral Pedicled Anterolateral Thigh Flap (ATL) for Upper Thigh Defect in the Era of Free ATL?
por: Hulika, Narendra, et al.
Publicado: (2016)

Upper cold box 12KW.
por: Jean-Luc Caron
Publicado: (1998)

Technical Specification for a high voltage 120 kW (180 kW peak) power supply
por: Höfle, Wolfgang
Publicado: (2000)

Mogamulizumab Treatment in a Hemodialysis Patient with Adult T-Cell Leukemia/Lymphoma
por: Yoshihara, Mari, et al.
Publicado: (2014)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T‐cell leukemia‐lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_57d5lj1vdoe2eif2v1ckkrcd7s